TheStreet tracks the top 10 clinical trials to watch

TheStreet's top biotech stock ace, Adam Feuerstein, has culled through a mountain of releases and reports to come up with the 10 most closely-watched trial announcements expected in the second half of the year. His list includes: Ariad's Phase III data for the sarcoma drug ridaforolimus, which Merck licensed; AstraZeneca's zibotentan, which hopes to answer the question about who has the next Provenge to offer the market; as well as mid-stage data on BioMarin's Peg-Pal for phenylketonuria,...